*ST雙成(002693.SZ):半年度預虧1300萬元–1900萬元
格隆匯7月14日丨*ST雙成(002693.SZ)公佈2025年半年度業績預告,1-6月公司實現歸屬於上市公司股東的淨利潤虧損1,300萬元–1,900萬元,扣除非經常性損益後的淨利潤虧損1,555萬元-2,155萬元,基本每股收益虧損0.0313元/股–0.0458元/股,營業收入7,500萬元–9,500萬元,扣除後營業收入7,200萬元–9,200萬元。
醫藥行業改革不斷深化,市場供求和價格變動較大,集採未中標品種銷量下降明顯,中標品種價格大幅下降,公司主要品種注射用胸腺法新在集採新標期同樣降價中標,導致境內銷售利潤有所減少。2025年5月注射用紫杉醇(白蛋白結合型)簡略新藥申請(ANDA)獲得美國食品和藥品監督管理局(FDA)的上市許可批準並已實現出口銷售,以及注射用比伐蘆定產品出口收入增長,使得出口利潤提升。以上因素導致總體業績變動不大。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.